Paper42016288
High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.
Dai Y and 5 others. J Hepatocell Carcinoma, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients. Papers, record 42016288. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42016288
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 2 | 15305374 | High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. | Int J Cancer | 2004 | https://conductscience.org/library/papers/15305374 | PubMed |
| 3 | 39036382 | Cancer incidence and mortality in China, 2022. | J Natl Cancer Cent | 2024 | https://conductscience.org/library/papers/39036382 | PubMed |
| 4 | 30896550 | Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. | Eur J Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30896550 | PubMed |
| 5 | 38118280 | Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma. | J Natl Compr Canc Netw | 2023 | https://conductscience.org/library/papers/38118280 | PubMed |
| 6 | 27638177 | Structural Biology and Evolution of the TGF-β Family. | Cold Spring Harb Perspect Biol | 2016 | https://conductscience.org/library/papers/27638177 | PubMed |
| 7 | 22416010 | Diagnostic value of serum activin A and follistatin levels in women with peritoneal, ovarian and deep infiltrating endometriosis. | Hum Reprod | 2012 | https://conductscience.org/library/papers/22416010 | PubMed |
| 8 | 39281724 | Cancer survival statistics in China 2019-2021: a multicenter, population-based study. | J Natl Cancer Cent | 2024 | https://conductscience.org/library/papers/39281724 | PubMed |
| 9 | 20623366 | Serum follistatin in patients with prostate cancer metastatic to the bone. | Clin Exp Metastasis | 2010 | https://conductscience.org/library/papers/20623366 | PubMed |
| 10 | 31757999 | Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. | Sci Rep | 2019 | https://conductscience.org/library/papers/31757999 | PubMed |
| 11 | 35142813 | Tumor Size, Not Small Vessel Invasion, Predicts Survival in Patients With Hepatocellular Carcinoma. | Am J Clin Pathol | 2022 | https://conductscience.org/library/papers/35142813 | PubMed |
| 12 | 23456439 | Follistatin as potential therapeutic target in prostate cancer. | Target Oncol | 2013 | https://conductscience.org/library/papers/23456439 | PubMed |
| 13 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 14 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 15 | 38172802 | Impact of tumor size on the outcomes of hepatic resection for hepatocellular carcinoma: a retrospective study. | BMC Surg | 2024 | https://conductscience.org/library/papers/38172802 | PubMed |
| 16 | 35037070 | Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors. | Cancer Immunol Immunother | 2022 | https://conductscience.org/library/papers/35037070 | PubMed |
| 17 | 34624411 | Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. | J Hepatol | 2022 | https://conductscience.org/library/papers/34624411 | PubMed |
| 18 | 33343207 | Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. | Curr Oncol | 2020 | https://conductscience.org/library/papers/33343207 | PubMed |
| 19 | 11726573 | Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. | Hum Reprod | 2001 | https://conductscience.org/library/papers/11726573 | PubMed |
| 20 | 3120188 | Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. | Proc Natl Acad Sci U S A | 1987 | https://conductscience.org/library/papers/3120188 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| FST | 10468 | PubTator's text mining | https://conductscience.org/library/genes/10468 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42016288
GET https://conductscience.org/api/papers/v1/42016288/references?page=2